Freddie Dear
InvestorPrincipal (Portfolio) at Monograph Capital Partners · Board director at Nocion Therapeutics
London
About
Principal at Monograph who was part of the founding team of portfolio company Ascend Advanced Therapies and sits on the board of Nocion Therapeutics. Previously an Investment Partner at Syncona and part of the Wellcome Trust investment team.
Contact· self-published, not guessed
Board director at Nocion Therapeutics
Intro paths
→
In turn, Freddie can intro founders to Nocion Therapeutics's investors below.
Nocion Therapeutics's investors · 6
Canaan PartnersStamford · $500K – $20M checks · since 2025F-Prime CapitalCambridge · $3M – $10M checks · since 2024Mission BiocapitalSan Francisco · $500K checks · since 2024Monograph Capital PartnersLondon · since 2025Osage University PartnersBala Cynwyd · since 2024OUP (Osage University Partners)Bala Cynwyd · $1M – $20M checks
Experience
- Monograph CapitalPrincipalcurrent2024 — presentSan Francisco Bay Area
- Monograph CapitalPrincipal2021 — 2024Greater London, England, United Kingdom
- Nocion Therapeutics, Inc.Investor Directorcurrent2024 — present
- Ascend Advanced TherapiesStrategic Advisorcurrent2024 — presentSan Francisco Bay Area
- Ascend Advanced TherapiesVP, Corporate Development2024San Francisco Bay Area
- Ascend Advanced TherapiesVP, Corporate Development2022 — 2024Greater London, England, United Kingdom
- Ascend Advanced TherapiesHead of Corporate Development & Portfolio Manager2021 — 2022Greater London, England, United Kingdom
- Clade TherapeuticsBoard Observer2021
- Forcefield TherapeuticsBoard Observer2020 — 2021Greater London, England, United Kingdom
- Quell TherapeuticsBoard Observer2019 — 2021London Area, United Kingdom
- Quell TherapeuticsDirector Of Operations2019 — 2020London Area, United Kingdom
- Syncona LimitedInvestment Partner2018 — 2021London Area, United Kingdom
- Syncona LimitedSecondee2017 — 2018London Area, United Kingdom
- Wellcome TrustFinance and Investment graduate2016 — 2018London Area, United Kingdom
- Tetragon Financial Group LimitedInternship2015London Area, United Kingdom
Deals · 1
Nocion TherapeuticsBoard seat
via Monograph Capital Partners · filed Mar 2026 · $23M raise
Attribution from SEC filings, press coverage, and firm rosters.
Colleagues at Monograph Capital Partners
Bonnie van Wilgenburg
Principal at Monograph Capital Partners
Brandi O'Donnell
Chief of Staff & Executive Assistant at Monograph Capital Partners
Brandi O’Donnell
Chief of Staff & EA at Monograph Capital Partners
Charles Conn
Partner at Monograph Capital Partners
Charlie Zhou
Investment Manager at Monograph Capital Partners
Daniel Schwarz
Chief Financial Officer at Monograph Capital Partners
Fred Cohen
Partner and Chairman at Monograph Capital Partners
Jaideep Dudani
Principal at Monograph Capital Partners
Frequently asked questions
- Who is Freddie Dear?
- Principal at Monograph who was part of the founding team of portfolio company Ascend Advanced Therapies and sits on the board of Nocion Therapeutics. Previously an Investment Partner at Syncona and part of the Wellcome Trust investment team.
- Where does Freddie Dear work?
- Freddie Dear is Principal (Portfolio) at Monograph Capital Partners and Board director at Nocion Therapeutics.
- What boards does Freddie Dear sit on?
- Freddie Dear holds tracked board seats at Nocion Therapeutics.
- Where did Freddie Dear go to school?
- Freddie Dear studied at The University of Edinburgh (Bachelor of Science (BSc), Biochemistry).
Same school
.jpg)
Shared employers
Also worked at Monograph Capital12
Tim FunnellPartner at Monograph Capital PartnersCharles ConnPartner at Monograph Capital PartnersJaideep DudaniPrincipal at Monograph Capital PartnersCharlie ZhouInvestment Manager at Monograph Capital PartnersMelisa GuvenInvestment Manager at Monograph Capital PartnersMichelle HeInvestment Manager at Tin Alley Ventures
+ 6 more
